Using the industry peer median P/E Multiples multiple (trailing + forward), Gyre Therapeutics, Inc. (GYRE) has a fair value of $0.25 based on 1 comparable companies in the Biotechnology industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing P/E | Forward P/E | |
|---|---|---|---|
| Gyre Therapeutics, Inc.GYRE | 732 | 315.1x | — |
| Keros Therapeutics, Inc. | 442 | 5.2x | — |
| Industry Median | 5.2x | — | |
| (*) Profit after tax | 5 | ||
| Equity Value | 26 | ||
| (/) Outstanding shares | 103 | ||
| Fair Price | $0 | ||
Using the industry peer median EV/EBITDA multiple (trailing + forward), Gyre Therapeutics, Inc. (GYRE) has a fair value of $4.95 based on 1 comparable companies in the Biotechnology industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing EV/EBITDA | Forward EV/EBITDA | |
|---|---|---|---|
| Gyre Therapeutics, Inc.GYRE | 732 | 49.6x | 42.8x |
| Keros Therapeutics, Inc. | 442 | 2.4x | 56.3x |
| Industry Median | 2.4x | 56.3x | |
| (*) EBITDA | 14 | 16 | |
| = Enterprise Value | 33 | 916 | |
| (-) Net Debt | -36 | -36 | |
| Equity Value | 69 | 952 | |
| (/) Outstanding shares | 103 | 103 | |
| Fair Price | $1 | $9 | |
Using the industry peer median EV/Revenue multiple (trailing + forward), Gyre Therapeutics, Inc. (GYRE) has a fair value of $15.05 based on 4 comparable companies in the Biotechnology industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing EV/Revenue | Forward EV/Revenue | |
|---|---|---|---|
| Gyre Therapeutics, Inc.GYRE | 732 | 6.0x | 5.1x |
| Iovance Biotherapeutics, Inc. | 1,095 | 3.7x | 2.6x |
| MeiraGTx Holdings plc | 766 | 9.7x | — |
| CytomX Therapeutics, Inc. | 749 | 9.7x | 33.5x |
| Keros Therapeutics, Inc. | 442 | 0.7x | 16.6x |
| Industry Median | 6.7x | 16.6x | |
| (*) Revenue | 117 | 135 | |
| = Enterprise Value | 782 | 2,252 | |
| (-) Net Debt | -36 | -36 | |
| Equity Value | 818 | 2,289 | |
| (/) Outstanding shares | 103 | 103 | |
| Fair Price | $8 | $22 | |
Using the PEG framework with historical EPS growth of 8.0%, the company has a fair value of $0.18 based on TTM EPS (FY2025) of $0.02.
| EPS Growth RateHistorical | -55.0% |
| Adjusted Growth (clamped 8–25%)Clamped | 8.0% |
| Fair P/E | 8.0x |
| TTM EPS (FY2025) | $0.02 |
| Fair Value | $0.18 |
No analyst estimates available.
| Year | Net Income | EPS | YoY |
|---|---|---|---|
| FY2021 | $-87.9M | $-2.87 | — |
| FY2022 | $2.3M | $0.03 | — |
| FY2023 | $-92.9M | $-1.41 | -4800.0% |
| FY2024 | $12.1M | $0.05 | — |
| FY2025 | $5.0M | $0.02 | -55.0% |
4Y Historical EPS CAGR: -55.0%
Disclaimer: Sweet Value Lab provides estimated intrinsic values for informational purposes only. This is not financial advice. All models rely on assumptions that may not reflect future performance. Always do your own research before making investment decisions.